245 related articles for article (PubMed ID: 27872058)
1. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Knapper S; Russell N; Gilkes A; Hills RK; Gale RE; Cavenagh JD; Jones G; Kjeldsen L; Grunwald MR; Thomas I; Konig H; Levis MJ; Burnett AK
Blood; 2017 Mar; 129(9):1143-1154. PubMed ID: 27872058
[TBL] [Abstract][Full Text] [Related]
2. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Levis M; Ravandi F; Wang ES; Baer MR; Perl A; Coutre S; Erba H; Stuart RK; Baccarani M; Cripe LD; Tallman MS; Meloni G; Godley LA; Langston AA; Amadori S; Lewis ID; Nagler A; Stone R; Yee K; Advani A; Douer D; Wiktor-Jedrzejczak W; Juliusson G; Litzow MR; Petersdorf S; Sanz M; Kantarjian HM; Sato T; Tremmel L; Bensen-Kennedy DM; Small D; Smith BD
Blood; 2011 Mar; 117(12):3294-301. PubMed ID: 21270442
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
Leukemia; 2021 May; 35(5):1279-1290. PubMed ID: 33623141
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
Knapper S; Burnett AK; Littlewood T; Kell WJ; Agrawal S; Chopra R; Clark R; Levis MJ; Small D
Blood; 2006 Nov; 108(10):3262-70. PubMed ID: 16857985
[TBL] [Abstract][Full Text] [Related]
7. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
8. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
9. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
Mead AJ; Gale RE; Kottaridis PD; Matsuda S; Khwaja A; Linch DC
Br J Haematol; 2008 May; 141(4):454-60. PubMed ID: 18341639
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
12. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
13. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
14. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
17. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
18. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.
Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H;
Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of FLT3 in AML: a focus on sorafenib.
Antar A; Otrock ZK; El-Cheikh J; Kharfan-Dabaja MA; Battipaglia G; Mahfouz R; Mohty M; Bazarbachi A
Bone Marrow Transplant; 2017 Mar; 52(3):344-351. PubMed ID: 27775694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]